Cytosorbents Cor (CTSO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Sales | 8,864 | 9,234 | 9,485 | 9,617 | 8,727 |
| Cost of Goods | 2,734 | 2,430 | 2,819 | 2,803 | 2,520 |
| Gross Profit | 6,130 | 6,804 | 6,666 | 6,814 | 6,207 |
| Operating Expenses | 9,908 | 11,618 | 10,347 | 11,232 | 10,615 |
| Operating Income | -3,044 | -4,384 | -2,862 | -3,615 | -3,888 |
| Interest Expense | 857 | 746 | 645 | 616 | 605 |
| Other Income | -1,228 | -366 | -64 | 6,178 | 3,014 |
| Pre-tax Income | -5,129 | -5,496 | -3,571 | 1,947 | -1,479 |
| Income Tax | N/A | N/A | -401 | N/A | N/A |
| Net Income Continuous | -5,129 | -5,496 | -3,170 | 1,947 | -1,479 |
| Net Income | $-5,129 | $-5,496 | $-3,170 | $1,947 | $-1,479 |
| EPS Basic Total Ops | -0.08 | -0.09 | -0.05 | 0.03 | -0.02 |
| EPS Basic Continuous Ops | -0.08 | -0.09 | -0.05 | 0.03 | -0.02 |
| EPS Diluted Total Ops | -0.08 | -0.09 | -0.05 | 0.03 | -0.02 |
| EPS Diluted Continuous Ops | -0.08 | -0.09 | -0.05 | 0.03 | -0.02 |
| EPS Diluted Before Non-Recurring Items | N/A | -0.09 | -0.04 | -0.05 | -0.06 |
| EBITDA(a) | $-2,377 | $-3,750 | $-2,271 | $-2,984 | $-3,293 |